Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3127634 | 1.00 | NPC1 (0.42) | NPC1RAB9AGPR119USP30IDO1 | |
| SCHEMBL3136405 | 0.92 | USP30 (0.37) | NPC1RAB9AGPR119USP30LIPE | |
| SCHEMBL3130127 | 0.92 | USP30 (0.37) | NPC1RAB9AGPR119USP30LIPE | |
| SCHEMBL3130120 | 0.92 | USP30 (0.37) | NPC1RAB9AGPR119USP30LIPE | |
| SCHEMBL3135530 | 0.86 | ESR2 (0.38) | GPR119USP30LIPE | |
| SCHEMBL5846934 | 0.84 | NPC1 (0.41) | NPC1RAB9AGPR119USP30IDO1 | |
| SCHEMBL5847677 | 0.84 | NPC1 (0.41) | NPC1RAB9AGPR119USP30IDO1 | |
| SCHEMBL3140288 | 0.84 | MAPT (0.52) | NPC1RAB9AGPR119 | |
| SCHEMBL5847390 | 0.83 | FPR2 (0.42) | NPC1RAB9AGPR119USP30IDO1 | |
| SCHEMBL5848322 | 0.81 | NPC1 (0.40) | NPC1RAB9AGPR119USP30IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399445-B9 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-1399445-B1 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-08-05 | — | — | EP | disclosed |
| US-6777406-B2 | SUCH AS PYRIDO(3,2,1-IJ)PYRROLO(3,4-C)QUINOLIN-8-ONE DERI-VATIVES; CENTRAL NERVOUS SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040092502-A1 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092502-A1 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | HTR1B, HTR2B, HTR1A | NPC1 1598/4885RAB9A 177/4885GPR119 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.